Literature DB >> 22589673

Neurodevelopmental outcome of newborns with persistent pulmonary hypertension.

Jaafar Rohana1, Nem Yun Boo, Viji Chandran, Rajini Sarvananthan.   

Abstract

BACKGROUND: Developmental disabilities have been reported in infants with persistent pulmonary hypertension of the newborn (PPHN) treated with inhaled nitric oxide (INO) or intravenous magnesium sulphate (MgSO(4)) and/or extracorporeal membrane oxygenation. This paper reports the rate of developmental disabilities at 2 years of age in a cohort of survivors of PPHN treated with INO, MgSO(4), or both during the neonatal period.
METHODS: Sixteen survivors of PPHN were prospectively followed up. These infants were treated with intravenous MgSO(4) and/or INO during the neonatal period. Neurodevelopmental assessment was carried out at 2 years of age using the Bayley Scales of Infant Development 2nd Edition by a developmental psychologist. Eleven (68.8%) infants completed the 2-year follow-up.
RESULTS: The median mental developmental index (MDI) and physical developmental index scores were 85 (interquartile range, IQR = 27) and 87 (IQR = 33), respectively. Two infants (18.2%) had developmental disability (MDI scores <70).
CONCLUSION: Survivors of PPHN are at risk of developmental disabilities. Early intervention programme and long-term follow-up should be integrated in the management of these infants.

Entities:  

Keywords:  developmental disabilities; magnesium sulphate; neurology; nitric oxide; persistent pulmonary hypertension of newborn

Year:  2011        PMID: 22589673      PMCID: PMC3328938     

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  11 in total

1.  Longitudinal follow-up of a cohort of newborn infants treated with inhaled nitric oxide for persistent pulmonary hypertension.

Authors:  A A Rosenberg; J M Kennaugh; S G Moreland; L M Fashaw; K A Hale; F M Torielli; S H Abman; J P Kinsella
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

2.  Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn.

Authors:  J P Kinsella; W E Truog; W F Walsh; R N Goldberg; E Bancalari; D E Mayock; G J Redding; R A deLemos; S Sardesai; D C McCurnin; S G Moreland; G R Cutter; S H Abman
Journal:  J Pediatr       Date:  1997-07       Impact factor: 4.406

3.  Inhaled nitric oxide and intravenous magnesium sulphate for the treatment of persistent pulmonary hypertension of the newborn.

Authors:  N Y Boo; J Rohana; S C Yong; A Z Bilkis; F Yong-Junina
Journal:  Singapore Med J       Date:  2010-02       Impact factor: 1.858

4.  Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide.

Authors:  Paul H Lipkin; Dennis Davidson; Lynn Spivak; Richard Straube; Jared Rhines; C T Chang
Journal:  J Pediatr       Date:  2002-03       Impact factor: 4.406

5.  Child health status, neurodevelopmental outcome, and parental satisfaction in a randomized, controlled trial of nitric oxide for persistent pulmonary hypertension of the newborn.

Authors:  M Ellington; D O'Reilly; E N Allred; M C McCormick; D L Wessel; S Kourembanas
Journal:  Pediatrics       Date:  2001-06       Impact factor: 7.124

6.  Neonatal encephalopathy following fetal distress. A clinical and electroencephalographic study.

Authors:  H B Sarnat; M S Sarnat
Journal:  Arch Neurol       Date:  1976-10

7.  Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate.

Authors:  Y K Abu-Osba; O Galal; K Manasra; A Rejjal
Journal:  Arch Dis Child       Date:  1992-01       Impact factor: 3.791

8.  Three-year follow up of term and near-term infants treated with inhaled nitric oxide.

Authors:  Hiroyuki Ichiba; Satoko Matsunami; Fumihide Itoh; Toru Ueda; Yukinobu Ohsasa; Tsunekazu Yamano
Journal:  Pediatr Int       Date:  2003-06       Impact factor: 1.524

9.  Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn.

Authors:  J F Tolsa; J Cotting; N Sekarski; M Payot; J L Micheli; A Calame
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-05       Impact factor: 5.747

10.  High prevalence of minor neurologic deficits in a long-term neurodevelopmental follow-up of children with severe persistent pulmonary hypertension of the newborn: a cohort study.

Authors:  Anna Berti; Augusta Janes; Riccardo Furlan; Francesco Macagno
Journal:  Ital J Pediatr       Date:  2010-06-13       Impact factor: 2.638

View more
  2 in total

1.  A Descriptive Study on the Neonatal Morbidity Profile of Autism Spectrum Disorders, Including a Comparison with Other Neurodevelopmental Disorders.

Authors:  H Ó Atladóttir; D E Schendel; E T Parner; T B Henriksen
Journal:  J Autism Dev Disord       Date:  2015-08

Review 2.  Erythropoietin and Neonatal Neuroprotection.

Authors:  Sandra E Juul; Gillian C Pet
Journal:  Clin Perinatol       Date:  2015-05-14       Impact factor: 3.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.